AstraZeneca's Anselamimab Trial Update
AstraZeneca announced that its trial of Anselamimab for AL Amyloidosis did not achieve statistical significance across all patients, but ongoing evaluations show meaningful improvements in a specific subgroup. These results indicate significant progress compared to the placebo in terms of time to ACM and CVH frequency.

AstraZeneca PLC announced updates regarding Anselamimab in the treatment of AL Amyloidosis. While the results did not achieve statistical significance for the primary endpoint across the overall patient population, further evaluations remain ongoing.
Despite this, AstraZeneca reported clinically meaningful improvements in specific subgroups. In these groups, Anselamimab demonstrated significant progress compared to a placebo, particularly regarding the time to achieve acute care management (ACM) and the frequency of cardiovascular hospitalizations (CVH).
The ongoing assessment of Anselamimab suggests promising outcomes, despite initial setbacks, underscoring AstraZeneca's commitment to exploring its potential benefits further.
(With inputs from agencies.)
ALSO READ
Welcure Drugs & Pharmaceuticals Secures Major Export Orders
Fredun Pharmaceuticals Enters Pet Care Market with Strategic Acquisition of One Pet Stop
Alembic Pharmaceuticals Acquires Utility Therapeutics for Strategic US Expansion
Trump Plans High Tariffs on Semiconductors and Pharmaceuticals
Asston Pharmaceuticals Launches Landmark IPO